Company news
Hutchmed (china) Limited (HKEX:13) news
Every Hutchmed (china) Limited press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
September 3, 2026
HUTCHMED Reports 2026 Interim Results
July 30, 2026
HUTCHMED to Announce 2026 Half-Year Financial Results
June 30, 2026
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
May 21, 2026
HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
April 29, 2026